Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Avanos Medical (AVNS) EBITDA Margin (2016 - 2025)

Avanos Medical's EBITDA Margin history spans 11 years, with the latest figure at 7.04% for Q3 2024.

  • For Q3 2024, EBITDA Margin rose 634.0% year-over-year to 7.04%; the TTM value through Sep 2024 reached 4.92%, up 342.0%, while the annual FY2023 figure was 7.87%, 1496.0% down from the prior year.
  • EBITDA Margin for Q3 2024 was 7.04% at Avanos Medical, up from 3.67% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 11.57% in Q4 2022 and bottomed at 62.57% in Q4 2021.
  • The 5-year median for EBITDA Margin is 0.33% (2020), against an average of 3.49%.
  • The largest annual shift saw EBITDA Margin tumbled -3706bps in 2021 before it soared 7414bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 25.51% in 2020, then crashed by -145bps to 62.57% in 2021, then soared by 118bps to 11.57% in 2022, then crashed by -44bps to 6.46% in 2023, then increased by 9bps to 7.04% in 2024.
  • Per Business Quant, the three most recent readings for AVNS's EBITDA Margin are 7.04% (Q3 2024), 3.67% (Q2 2024), and 2.41% (Q1 2024).